Menu
← Oncology Approval Tracker
FDA DECISION ·
Bynfezia Pen
octreotide acetate · Sun Pharmaceutical Industries
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous octreotide pen for adults with severe diarrhea or flushing associated with metastatic carcinoid tumors, or profuse watery diarrhea due to VIP-secreting tumors.
LAMPGEN ANALYSIS
Why it matters
This was the pen’s initial authorization for the labeled tumor-related symptoms. FDA later rescinded the original approval and reapproved the pen in 2024.
What research teams should watch
Track the product and presentation in medication records and verify that patients have received training on pen dosing and disposal.
PRIMARY RECORDS